贝伐珠单抗联合化学药物治疗晚期胃癌的疗效观察

Clinical observation of bevacizumab plus chemotherapy for advanced gastric cancer

目的:贝伐珠单抗是血管内皮生长因子的重组人源化单克隆IgGl抗体,通过抑制肿瘤血管生成而发挥抗肿瘤作用。本研究旨在观察贝伐珠单抗联合化学药物治疗晚期胃癌的疗效与安全性。方法:12例晚期胃癌患者均经病理组织学确诊后接受贝伐珠单抗联合化学药物治疗。贝伐珠单抗的剂量为7.5 mg/kg,第1天给药,21 d 1个周期,每2个周期评价疗效。结果:12例患者均可评价疗效和毒副反应,一线治疗5例,二线治疗7例,根据实体瘤的疗效(response evaluation criteria insolid tumors,RECIST)评定标准,无完全缓解患者,部分缓解8例(66.7%),病情稳定3例(25.0%),病情进展1例(8.3%),客观有效率67%,疾病控制率91%。中位无进展生存时间5.5个月,中位总生存期7.0个月。骨髓抑制6例,肝损害3例,胃肠道反应2例,高血压1例,均为I^II度,经对症治疗后好转,无严重不良事件。结论:贝伐珠单抗联合化学药物治疗晚期胃癌临床疗效较好,用药期间不良反应可耐受。

Objective： Bevacizumab （avastin） is a recombinant human monodonal IgG1 antibody for vascular endothelial growth factor （VEGF）, and it shows an antitumor effect by inhibition of tumor angiogenesis. This study is to evaluate the effect of bevacizumab plus chemotherapy on advanced gastric cancer, and observe the safety in the meanwhile. Methods： Twelve patients with advanced gastric cancer confirmed dearly by histopathology received bevacizumab plus chemotherapy. l-he dose of bvacizumab was 7.$ mg/kg at Day 1, with a 21-day cycle, efficacy evaluation for every 2 cycles. Results： Efficacy was evaluated and side effect was observed in 12 patients. Of the patients, a first-line regimen was used in 5 patients and a second-line regimen was used in 7 patients. According to the standard of response evaluation criteria in solid tumors （RECIST）, the results were as follows： No patients with complete remission 8 partial remissionj 3 stable remission and 1 progression disease. The ob）ective response rate was 67% and the disease control rate was 91%. The＇median progression-free survival time （mPFS） was 5.5 months and the median overall survival （mOS） was 7.0 months. Six patients had bone marrow suppressiong 3 liver iniur 2 gastrointestinal reactions and 1 hypertension~ in which all toxicities were Grade I-II and all adverse reactions recovered after symptomatic treatment. No serious accident was occurred. Conclusion： The regimen of bevacizumab plus chemotherapy can well improve the response rate for advanced gastric cancer and Side reactions can be tolerated by patients.